Immunoblotting after DCLK1-IN-1 treatment showed a reduction in the expression of the mesenchymal marker N-Cadherin in all RCC cell lines (Figure 2A), which was accompanied by significantly decreased cell migration and invasion (Figure 2B–D). Here, DCLK1 is linked to renal cell carcinoma.